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Abstract
Although the solitary pulmonary nodule (SPN) is a common presentation of lung cancer, most SPNs are benign. The
challenge in evaluating SPNs is to avoid invasive procedures in patients who have benign nodules, without allowing
potentially curable bronchogenic carcinomas the time to progress to more advanced or even unresectable disease.
Various approaches include assessment of nodule morphology, interval growth and contrast enhancement, as well as
techniques such as percutaneous biopsy, positron emission tomography scanning and depreotide imaging. The role of
each of these approaches is discussed.
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Introduction
Although the solitary pulmonary nodule (SPN) is a
common presentation of lung cancer, most SPNs are
benign. The challenge in evaluating SPNs is to avoid
invasive procedures in patients who have benign nod-
ules without allowing potentially curable bronchogenic
carcinomas the time to progress to more advanced
or even unresectable disease. Whereas calcification is
the single best morphologic indicator of benignancy,
behavior (i.e. lack of growth) is far better than
any morphologic criterion at predicting benignancy.
Any predictor of benignancy must err on the side
of intervention—it is better to resect a benign SPN
unnecessarily than erroneously to call a malignant SPN
benign.
Calcification
At the current time, most patients with a non-calcified
SPN at chest radiography and no comparison films
go to CT. Thin-section CT facilitates the detection of
calcification that could be missed on chest radiographs;
the thickness of the sections used should be no larger
than half the diameter of the nodule, in order to avoid
partial volume averaging with adjacent lung tissue, and
all images should be obtained during a single breath
hold, in order to eliminate scan plane mis-registration.
Although CT densitometry using a reference phantom
(a cylinder filled with a calcium-containing substance
that serves as a standard of comparison to assess density
of a patient’s nodule) has been helpful in the past,
improvements in scanner technology have made use of
the phantom largely unnecessary; in current practice
it is rarely, if ever, used. If calcification is identified,
the pattern of calcification should be considered when
evaluating a nodule. Granulomas typically show diffuse
or near-complete calcification or a central nidus of
calcification. The finding of multiple large, scattered
calcifications in a ‘popcorn’ pattern is highly suggestive
of a hamartoma; the diagnosis is confirmed if portions
of the nodule show fatty attenuation, with or without
associated calcification (Fig. 1). It should be remembered
that not all calcifications are benign: carcinomas may
occasionally show stippled and/or eccentric calcifica-
tion.
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Contrast enhancement
Preliminary studies with follow-up of non-calcified SPNs
have reported that all, or nearly all, malignant SPNs
enhance by at least 20 Hounsfield units (HU) within
2–4 min after contrast injection; few benign SPNs
enhance to that degree. Based on these promising
preliminary results, a multi-center study subsequently
evaluated 356 SPNs that were 5–40 mm, solid, relatively
spherical, homogeneous and without calcification or fat
on non-contrast images. Contrast-enhanced images were
obtained at 1–4 min after onset of injection (3 mm
collimation, 420 mgI/kg, 300 mgI/ml administered at
2 ml/s). CT showed 98% sensitivity, 58% specificity
and 77% accuracy in diagnosing malignancy, using a
threshold of 15 HU [1]. Prevalence of malignancy in this
patient group was 48% (171/356 nodules). Using this
technique, false-negative exams may occur occasionally
in necrotic or mucin-producing tumors. The authors
suggest using the lung nodule enhancement technique in
lesions that are≤2 cm in diameter; lesions of this size are
less likely to be necrotic, are more likely to be benign,
and are often difficult to percutaneously biopsy. The low
specificity (high false-positive rate) may be explained
by an additional study that demonstrated overlap in
enhancement of malignant lesions and benign lesions
with active inflammation [2]. Perhaps because of the low
specificity, this technique currently plays a minor role in
the work-up of the SPN at most institutions.
CT follow-up imaging
If a patient and physician opt to follow a nodule using
CT, then a high-quality baseline study should be obtained
using 1–1.25 mm thick sections. Therefore, if a nodule is
initially detected on a low-dose lung cancer screening CT,
or other CT performed using relatively thick sections, the
patient should be brought back for a standard dose, thin-
section, diagnostic CT. All subsequent studies should be
performed using the same techniques, to allow optimal
comparison. Follow-up CT imaging may be performed
at 3-month intervals for the first year, and at 6-month
intervals for the second year.
(a) (b)
Figure 1 Benign calcification. Lung nodule shows
fat and calcium in a ‘popcorn’ pattern, consistent with
a hamartoma.
Two preliminary studies that looked at nodule phan-
toms and real patient nodules found that thin-section CT
could enable detection of very minute changes in lung
nodule cross-sectional areas and volumes [3]. Volume
assessment appeared to be superior to cross-sectional
area assessment due to the potential for asymmetric
growth, particularly in the cranio–caudal direction. An
important aspect of these studies was the use of
automatic segmentation for lesion boundary definition,
thus eliminating observer bias and other sources of
manual edge determination. The authors concluded that
repeat CT at 30 days can detect growth for most
neoplasms that are at least 5 mm in diameter, assuming
typical doubling times of ≤180 days. This observation
has very important implications for the work-up of a lung
nodule, with the potential to obviate many other invasive
and/or expensive procedures. However, this technique
will not be ready for routine clinical use until it is
confirmed in other, larger studies and until automatic
segmentation becomes widely available. In fact, other
authors have found that a large proportion of tumors have
much longer doubling times (≥465 days), and therefore
short-term follow-up may not be helpful [4].
Percutaneous biopsy
In some centers, nodules that are indeterminate at
CT densitometry may be percutaneously biopsied; high
accuracies have been reported, with a positive predictive
value of 99%. The real challenge, of course, is to make
a negative biopsy accurate and furthermore to establish
a specific benign diagnosis. Using systematic staining
and culture schemes, high negative predictive values have
been reported for patients in whom a specific benign
diagnosis could be made. However, the negative predic-
tive value is generally lower in patients with a biopsy
showing non-specific inflammation. Recently published
studies have reported overall negative predictive values
ranging from 52 to 84% [5].
In a patient with a high pre-test probability of harboring
lung cancer, a positive percutaneous biopsy will lead to
thoracotomy. On the other hand, a non-specific negative
biopsy in such a patient may not be sufficiently reliable
due to sampling error, and many surgeons will resect
the nodule regardless of the biopsy results. Therefore,
preoperative biopsy is generally not indicated in patients
with a high probability of malignancy [6]. An exception
would occur in the patient with a history of previous
extrathoracic primary neoplasm. At some institutions, it
is advocated that a non-specific negative percutaneous
biopsy of an SPN be followed by a repeat biopsy. If the
repeat biopsy is also negative for neoplasm, then close
follow-up is advised. Some investigators have suggested
the use of core or cutting needle biopsies to increase
the yield of specific benign diagnoses [7]; unfortunately
such biopsies do not appear to change the overall false-
negative rate compared to fine-needle aspiration biopsy
(generally approximately 15–25%). Thus, a non-specific
negative biopsy result should be viewed with caution.
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Positron emission tomography (PET)
The ability of FDG–PET to separate malignant from
benign lesions is high (accuracy approximately 90%), but
not totally perfect (Fig. 2) [8,9]. Nodules less than 8 mm in
diameter may be particularly difficult to evaluate because
of their small size relative to the resolution of the PET
scanner. High tracer uptake can sometimes be seen in an
inflammatory or infectious process, such as aspergillosis
or TB. False-negative scans sometimes occur in patients
with bronchioloalveolar cell carcinoma and carcinoids,
tumors that have considerably lower uptake of FDG
than other lung cancers. With a prevalence of 4–10%
false-negatives, there are risks of missing tumors if PET
is the only test performed. Most investigators would
recommend follow-up imaging tests of SPNs following
a negative PET to exclude tumor growth, as a small
percentage of patients with negative PET scans of SPN
will have malignant tumors present. At many centers,
PET is carried out in the more clinically challenging
cases, such as the difficult-to-biopsy lesions (e.g. patients
with severe emphysema), or in patients who are at greater
than usual risk at surgical assessment/biopsy.
(a) (b)
Figure 2 New, primary bronchogenic carcinoma in
a patient who has undergone previous esophagectomy
and gastric pull-through for esophageal carcinoma.
CT (a) shows an SPN that is FDG avid at PET (b).
Depreotide imaging
Initial studies have been done using a relatively new
metabolic imaging agent, Tc 99m-depreotide, for distin-
guishing benign from malignant pulmonary nodules [10].
A multi-center study involving 114 patients found 97%
sensitivity and 73% specificity in diagnosing lung cancer.
Thus this imaging technique is promising, particularly for
use in centers without access to a PET scanner.
Conclusion
Distinguishing between benign and malignant SPNs is an
area of active, ongoing research. Various approaches may
be considered, depending upon patient circumstances and
available technology.
Key points
• Thin-section CT facilitates the detection of calcifica-
tion and the assessment of a benign vs. a malignant
pattern of calcification.
• A non-specific, negative percutaneous biopsy should
be viewed with caution, as it does not necessarily
exclude malignancy.
• The ability of FDG–PET to separate malignant from
benign SPNs is high (accuracy approximately 90%),
but not totally perfect.
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